In preclinical models of tumors overexpressing indoleamine 2,3-dioxygenase 1 (IDO), blocking hydrocarbon receptors improved the therapeutic efficacy of immune checkpoint blockade by disrupting immune suppression mediated by Tregs and tumor-associated macrophages13. The gene discussed is IDO1; the disease is neoplasm.